[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Primary liver cancer with lymph node metastasis was recognized as poor prognosis. We herein report a case of post operative lymph node recurrence treated with UFT. A 74-year-old man with a huge mass lesion in the right liver with para Aortic lymph node metastasis admitted our hospital in April 2007. Extended right lobe hepatectomy and lymph node dissection were performed in May. A histological examination of the resected specimen showed a combined hepatocellular-cholangiocarcinoma with three lymph node metastasis. Computed tomography(CT)revealed intra hepatic metastasis (S3) and right adrenal grand metastasis 5 months after surgery. Transarterial embolization (TAE) and right adrenalectomy were performed for each metastasis. CT revealed a lymph node metastasis at the right side of infra vena cava 1 year after surgery. He was treated by oral administration of UFT (200 mg/day). The AFP and PIVKA-II value gradually decreased after administration of UFT. The size of lymph node metastasis became small confirmed by CT. But the AFP and PIVKA-II value increased 1 year and 7 months after surgery. TAE was performed against lymph node metastasis 1 year and 9 months after surgery. This case suggests UFT is useful for suppressing the growth of the lymph node metastasis.
Shimizu
Junzo
J
Department of Surgery, Toyonaka Municipal Hospital.
Hayashi
Shoho
S
Dono
Keizo
K
Yasumoto
Taku
T
Zenitani
Masahiro
M
Munakata
Kouji
K
Watanabe
Noriyuki
N
Takamoto
Kaori
K
Kagawa
Yoshinori
Y
Hata
Taishi
T
Kawanishi
Kensyu
K
Ikeda
Kimimasa
K
Fujita
Junya
J
Akagi
Kenzo
K
Kitada
Masashi
M
Shimano
Takashi
T
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology*; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D009364:Neoplasm Recurrence, Local; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D014498:Uracil